UCB SA (OTCMKTS:UCBJF) Given Consensus Recommendation of “Buy” by Brokerages

Shares of UCB SA (OTCMKTS:UCBJF) have been assigned an average recommendation of “Buy” from the six ratings firms that are currently covering the stock, Marketbeat.com reports. Six equities research analysts have rated the stock with a buy rating.

UCBJF has been the topic of a number of analyst reports. The Goldman Sachs Group reiterated a “buy” rating on shares of UCB in a research report on Monday, February 16th. Stephens reaffirmed an “overweight” rating on shares of UCB in a research note on Thursday, January 15th. Barclays reiterated an “overweight” rating on shares of UCB in a report on Tuesday, January 6th. Deutsche Bank Aktiengesellschaft reissued a “buy” rating on shares of UCB in a research report on Monday, December 8th. Finally, Wolfe Research began coverage on shares of UCB in a research note on Monday, February 23rd. They issued an “outperform” rating for the company.

UCB Stock Performance

OTCMKTS:UCBJF opened at $296.19 on Friday. The stock’s fifty day moving average is $311.16 and its 200 day moving average is $289.18. UCB has a fifty-two week low of $150.70 and a fifty-two week high of $345.39. The company has a debt-to-equity ratio of 0.33, a quick ratio of 0.78 and a current ratio of 1.19.

UCB Company Profile

UCB SA is a Belgium-based biopharmaceutical company focused on the discovery, development and commercialization of treatments for severe diseases of the immune system and the central nervous system. Founded in 1928 as Union Chimique Belge, the company transitioned from chemicals into pharmaceuticals and biologics and today concentrates its efforts on specialty medicines and research-driven innovation. UCB’s work spans small molecules and biologics, with an emphasis on improving outcomes for patients with chronic and complex conditions.

Key therapeutic areas for UCB include immunology and neurology, where the company markets several well-known products and maintains an active clinical pipeline.